Erythroid Promoter Confines FGF2 Expression to the Marrow after Hematopoietic Stem Cell Gene Therapy and Leads to Enhanced Endosteal Bone Formation

• Xianmei Meng,

  Affiliation Division of Regenerative Medicine, Department of Medicine, Loma Linda University, Loma Linda, California, United States of America

  ⨯
• David J. Baylink,

  Affiliation Division of Regenerative Medicine, Department of Medicine, Loma Linda University, Loma Linda, California, United States of America

  ⨯
• Matilda Sheng,

  Affiliation Division of Regenerative Medicine, Department of Medicine, Loma Linda University, Loma Linda, California, United States of America

  ⨯
• Hongjie Wang,

  Affiliation Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington, United States of America

  ⨯
• Daila S. Gridley,

  Affiliation Department of Radiation Medicine, Loma Linda University, Loma Linda, California, United States of America

  ⨯
• K.-H. William Lau,

  Affiliation Musculoskeletal Disease Center, Jerry L. Pettis Memorial VA Medical Center, Loma Linda, California, United States of America

  ⨯
• Xiao-Bing Zhang

  * E-mail: xzhang@llu.edu

  Affiliation Division of Regenerative Medicine, Department of Medicine, Loma Linda University, Loma Linda, California, United States of America

  ⨯